• At least 18 years of age.

• Histologically or cytologically confirmed advanced solid tumors

‣ Arm #1 (Monotherapy): HRAS-mutant and/or amplified tumors (any solid tumor type); HRAS overexpression (only for HNSCC tumors); KRAS and/or NRAS, and/or HRAS-mutant and/or amplified NSCLC or CRC; KRAS-mutant and/or amplified PDAC

⁃ Arm #2 (Combination): Patients who have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC with predominantly clear cell subtype; non-clear cell RCC patients who are either treatment-naïve or have received any prior systemic treatment for locally advanced and metastatic RCC.

⁃ Arm #3 (Combination): Patients with KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC who have received at least 1 prior systemic therapy including available approved standard of care treatments.

• Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

• Karnofsky Performance Status of 70 or higher with no clinically significant deterioration over the previous 2 weeks.

• Acceptable liver, renal, endocrine, and hematologic function.

• Other protocol-defined inclusion criteria may apply.